Unity Biotechnology (UBX) Short Interest Ratio & Short Volume $1.13 +0.12 (+11.88%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Unity Biotechnology Short Interest DataUnity Biotechnology (UBX) has a short interest of 751,600 shares, representing 4.83% of the float (the number of shares available for trading by the public). This marks a 6.64% increase in short interest from the previous month. The short interest ratio (days to cover) is 3.6, indicating that it would take 3.6 days of the average trading volume of 118,946 shares to cover all short positions.Current Short Interest751,600 sharesPrevious Short Interest704,800 sharesChange Vs. Previous Month+6.64%Dollar Volume Sold Short$729,052.00Short Interest Ratio3.6 Days to CoverLast Record DateApril 15, 2025Outstanding Shares17,212,000 sharesFloat Size15,550,000 sharesShort Percent of Float4.83%Today's Trading Volume123,353 sharesAverage Trading Volume118,946 sharesToday's Volume Vs. Average104% Short Selling Unity Biotechnology? Sign up to receive the latest short interest report for Unity Biotechnology and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartUBX Short Interest Over TimeUBX Days to Cover Over TimeUBX Percentage of Float Shorted Over Time Unity Biotechnology Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/2025751,600 shares $729,052.00 +6.6%4.8%3.6 $0.97 3/31/2025704,800 shares $732,992.00 +10.1%4.6%2.6 $1.04 3/15/2025639,900 shares $1.13 million +15.3%4.2%2.4 $1.77 2/28/2025554,900 shares $948,879.00 +7.5%3.6%2.3 $1.71 2/15/2025516,300 shares $1.13 million +12.1%3.4%2.2 $2.19 1/31/2025460,400 shares $1.02 million +107.1%3.0%2 $2.22 1/15/2025222,300 shares $375,687.00 -8.9%1.5%1.1 $1.69 12/31/2024244,000 shares $238,241.60 -0.9%1.6%1.9 $0.98 12/15/2024246,100 shares $275,632.00 -4.8%1.6%3.6 $1.12 11/30/2024258,400 shares $320,416.00 -10.2%1.7%4.6 $1.24 Get the Latest News and Ratings for UBX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Unity Biotechnology and its competitors with MarketBeat's FREE daily newsletter. 11/15/2024287,600 shares $347,996.00 -5.1%1.9%5.7 $1.21 10/31/2024303,000 shares $412,080.00 -0.9%2.0%6.2 $1.36 10/15/2024305,700 shares $427,980.00 -1.6%2.0%7.5 $1.40 9/30/2024310,700 shares $456,729.00 +3.0%2.0%7.9 $1.47 9/15/2024301,800 shares $434,592.00 -8.9%2.0%7.4 $1.44 8/31/2024331,200 shares $539,856.00 +3.7%2.2%6.5 $1.63 8/15/2024319,500 shares $450,495.00 +5.5%2.1%5.7 $1.41 7/31/2024303,000 shares $463,590.00 -2.3%2.0%5.4 $1.53 7/15/2024310,100 shares $483,756.00 -3.8%2.0%5.4 $1.56 6/30/2024322,200 shares $434,970.00 0.0%2.1%5.4 $1.35 6/15/2024322,300 shares $460,889.00 -3.0%2.1%5.1 $1.43 5/31/2024332,400 shares $515,220.00 +7.1%2.2%5.5 $1.55 5/15/2024310,300 shares $474,759.00 -6.1%2.0%3.7 $1.53 4/30/2024330,400 shares $508,816.00 +8.4%2.2%3.8 $1.54 4/15/2024304,800 shares $457,200.00 -0.8%2.0%3.4 $1.50 3/31/2024307,200 shares $503,808.00 +5.4%2.0%3.4 $1.64 3/15/2024291,600 shares $437,400.00 +0.3%1.9%2.7 $1.50 2/29/2024290,600 shares $531,798.00 -9.2%1.9%2.6 $1.83 2/15/2024320,000 shares $636,800.00 +4.5%2.1%3.4 $1.99 1/31/2024306,100 shares $529,553.00 -0.3%2.0%3.1 $1.73 1/15/2024307,100 shares $571,206.00 -21.4%2.0%3.2 $1.86 12/31/2023390,700 shares $754,051.00 -15.6%N/A0 $1.93 12/15/2023463,100 shares $791,901.00 -7.7%3.1%5.5 $1.71 11/30/2023501,900 shares $963,648.00 -12.3%3.8%6.9 $1.92 11/15/2023572,500 shares $1.05 million -11.9%4.3%9.1 $1.83 10/31/2023649,600 shares $1.29 million +3.0%4.9%12.8 $1.99 10/15/2023630,900 shares $1.10 million -6.0%4.8%10.3 $1.75 9/30/2023670,900 shares $1.61 million -2.8%5.1%9.7 $2.40 9/15/2023690,400 shares $1.76 million -6.0%5.2%6.6 $2.55 8/31/2023734,600 shares $1.95 million -2.6%5.6%5.9 $2.65Top performing AI play of the decade…? (The answer will shock you) (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 8/15/2023754,500 shares $1.97 million -4.9%5.7%4.6 $2.61 7/31/2023793,500 shares $2.20 million +5.6%6.2%4.3 $2.77 7/15/2023751,800 shares $2.29 million -11.6%5.8%3.4 $3.05 6/30/2023850,300 shares $2.17 million +4.7%6.6%3.1 $2.55 6/15/2023811,900 shares $2.58 million -4.7%6.3%1.9 $3.18 5/31/2023851,900 shares $2.56 million -10.5%6.6%2 $3.01 5/15/2023952,200 shares $2.73 million -17.2%7.4%2.3 $2.87 4/30/20231,150,000 shares $2.46 million -4.2%9.2%2.6 $2.14 4/15/20231,200,000 shares $2.35 million -2.4%9.7%2.7 $1.96 3/31/20231,230,000 shares $2.00 million +21.8%9.9%3 $1.63 3/15/20231,010,000 shares $4.19 million +6.4%8.2%4.1 $4.15 2/28/2023949,000 shares $4.27 million +4.9%7.9%4.1 $4.50 2/15/2023904,900 shares $3.92 million +18.8%7.5%3.8 $4.33 1/31/2023761,600 shares $3.52 million +19.6%5.6%2.9 $4.62 1/15/2023636,700 shares $2.73 million +16.5%4.6%0.9 $4.29 12/30/2022546,500 shares $1.50 million -0.1%4.0%0.8 $2.74 12/15/2022547,000 shares $1.53 million -26.2%4.0%0.8 $2.79 11/30/2022740,900 shares $2.04 million -9.7%5.4%1.1 $2.75 11/15/2022820,100 shares $2.15 million +333.2%6.5%1.2 $2.62 10/31/2022189,300 shares $541,398.00 +68.3%1.5%0.2 $2.86 10/15/2022112,500 shares $441,000.00 -91.4%0.9%0.3 $3.92 9/30/20221,310,000 shares $517,581.00 -10.9%N/A0.3 $0.40 9/15/20221,470,000 shares $707,070.00 -17.0%N/A0.4 $0.48 8/31/20221,770,000 shares $822,696.00 +283.0%N/A0.5 $0.46 8/15/2022462,100 shares $596,109.00 +31.8%N/A0.1 $1.29 7/31/2022350,600 shares $232,588.04 +57.0%0.7%0.9 $0.66 7/15/2022223,300 shares $145,145.00 -38.2%0.4%0.6 $0.65 6/30/2022361,100 shares $203,479.85 -8.3%0.7%1 $0.56 6/15/2022393,800 shares $234,704.80 +0.8%0.8%1 $0.60 5/31/2022390,700 shares $308,653.00 -12.8%0.8%0.8 $0.79 5/15/2022448,000 shares $362,880.00 -35.5%0.9%0.8 $0.81 4/30/2022694,600 shares $632,086.00 -19.4%1.4%1.1 $0.91 4/15/2022861,800 shares $887,654.00 -3.5%1.8%1.2 $1.03 3/31/2022892,700 shares $999,824.00 +4.4%2.0%1.1 $1.12 3/15/2022855,100 shares $701,182.00 -20.1%1.9%0.8 $0.82 2/28/20221,070,000 shares $930,900.00 -8.6%2.8%1 $0.87 2/15/20221,170,000 shares $1.23 million +26.4%3.1%1.1 $1.05 1/31/2022925,400 shares $1.12 million +3.5%2.4%0.7 $1.21 1/15/2022894,100 shares $1.32 million +23.9%2.3%0.7 $1.48 12/31/2021721,600 shares $1.05 million -22.0%1.9%0.7 $1.46 12/15/2021925,100 shares $1.63 million -21.6%2.5%1 $1.76 11/30/20211,180,000 shares $2.60 million -4.1%3.2%1.4 $2.20 11/15/20211,230,000 shares $3.51 million +2.5%3.4%1.6 $2.85 10/29/20211,200,000 shares $2.87 million +1.7%3.4%2.8 $2.39 10/15/20211,180,000 shares $2.77 million -33.3%3.4%3 $2.35 9/30/20211,770,000 shares $5.31 million -31.4%5.1%4.6 $3.00 9/15/20212,580,000 shares $7.51 million -2.6%7.4%5.6 $2.91 8/31/20212,650,000 shares $8.48 million -0.8%7.6%5.7 $3.20 8/13/20212,670,000 shares $9.29 million -2.6%7.7%5.5 $3.48 7/30/20212,740,000 shares $9.97 million -9.9%7.9%5.4 $3.64Top performing AI play of the decade…? (The answer will shock you) (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 7/15/20213,040,000 shares $11.83 million +11.8%8.8%5.8 $3.89 6/30/20212,720,000 shares $12.62 million -20.0%7.9%5 $4.64 6/15/20213,400,000 shares $15.16 million +14.9%9.6%7.9 $4.46 5/28/20212,960,000 shares $13.26 million +11.3%8.4%7.1 $4.48 5/14/20212,660,000 shares $11.33 million +11.8%7.6%6 $4.26 4/30/20212,380,000 shares $12.14 million -8.5%7.8%4 $5.10 4/15/20212,600,000 shares $14.59 million +28.1%8.6%3.9 $5.61 3/31/20212,030,000 shares $11.65 million -12.5%6.9%2.7 $5.74 3/15/20212,320,000 shares $16.26 million +9.4%7.9%2.7 $7.01 2/26/20212,120,000 shares $14.37 million -12.4%7.4%2.3 $6.78 2/12/20212,420,000 shares $20.04 million -12.6%8.5%2.5 $8.28 1/29/20212,770,000 shares $16.45 million -9.2%9.5%3.2 $5.94 1/15/20213,050,000 shares $21.75 million -5.0%10.6%3.8 $7.13 12/31/20203,210,000 shares $17.17 million -0.6%10.6%4.2 $5.35 12/15/20203,230,000 shares $19.19 million +1.9%10.7%4.6 $5.94 11/30/20203,170,000 shares $20.16 million +1.3%11.3%4.1 $6.36 10/30/20202,730,000 shares $11.55 million -10.2%10.1%1.8 $4.23 10/15/20203,040,000 shares $11.89 million -8.2%11.4%1.8 $3.91 9/30/20203,310,000 shares $11.45 million -6.0%12.4%2 $3.46 9/15/20203,520,000 shares $12.43 million -1.4%13.2%2.2 $3.53 8/31/20203,570,000 shares $11.21 million -40.6%12.8%2.4 $3.14 8/14/20206,010,000 shares $74.70 million +11.7%22.8%4.4 $12.43 7/31/20205,380,000 shares $50.73 million +6.1%20.4%9.9 $9.43 7/15/20205,070,000 shares $39.04 million +1.2%20.4%14.3 $7.70 6/30/20205,010,000 shares $43.49 million +7.3%20.1%16.1 $8.68 6/15/20204,670,000 shares $39.41 million +8.1%18.6%16.2 $8.44 5/29/20204,320,000 shares $35.34 million +1.2%17.2%16.5 $8.18 5/15/20204,270,000 shares $27.80 million +1.4%17.0%18.5 $6.51 4/30/20204,210,000 shares $29.18 million -1.2%17.2%19.9 $6.93 UBX Short Interest - Frequently Asked Questions What is Unity Biotechnology's current short interest? Short interest is the volume of Unity Biotechnology shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 751,600 shares of UBX short. 4.83% of Unity Biotechnology's shares are currently sold short. Learn More on Unity Biotechnology's current short interest. What is a good short interest ratio for Unity Biotechnology? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. UBX shares currently have a short interest ratio of 4.0. Learn More on Unity Biotechnology's short interest ratio. Which institutional investors are shorting Unity Biotechnology? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Unity Biotechnology: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Unity Biotechnology? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.83% of Unity Biotechnology's floating shares are currently sold short. Is Unity Biotechnology's short interest increasing or decreasing? Unity Biotechnology saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 751,600 shares, an increase of 6.6% from the previous total of 704,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Unity Biotechnology's float size? Unity Biotechnology currently has issued a total of 17,212,000 shares. Some of Unity Biotechnology's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Unity Biotechnology currently has a public float of 15,550,000 shares. How does Unity Biotechnology's short interest compare to its competitors? 4.83% of Unity Biotechnology's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Unity Biotechnology: Inozyme Pharma, Inc. (10.15%), vTv Therapeutics Inc. (1.55%), Rani Therapeutics Holdings, Inc. (10.27%), Alto Neuroscience, Inc. (14.14%), Metagenomi, Inc. (12.67%), Adaptimmune Therapeutics plc (2.05%), Clearside Biomedical, Inc. (0.73%), InterCure Ltd. (0.10%), Achilles Therapeutics plc (1.26%), Vistagen Therapeutics, Inc. (1.98%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Unity Biotechnology stock? Short selling UBX is an investing strategy that aims to generate trading profit from Unity Biotechnology as its price is falling. UBX shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Unity Biotechnology? A short squeeze for Unity Biotechnology occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of UBX, which in turn drives the price of the stock up even further. How often is Unity Biotechnology's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including UBX, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies Inozyme Pharma Short Squeeze vTv Therapeutics Short Squeeze Rani Therapeutics Short Squeeze Alto Neuroscience Short Squeeze Metagenomi Short Squeeze Adaptimmune Therapeutics Short Squeeze Clearside Biomedical Short Squeeze InterCure Short Squeeze Achilles Therapeutics Short Squeeze Vistagen Therapeutics Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:UBX) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unity Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unity Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy UBX Stock Free UBX Stock Alerts